Scarica l'app Stockscreener
1.40
2.94%
0.04
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Canada
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
3 Biotech Stocks Surge with Momentum - National Today
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan
Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
What is HC Wainwright's Estimate for CRDL FY2028 Earnings? - MarketBeat
CARDIOL THERAPEUTICS INC (CRDL.NE) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cardiol Therapeutics Inc. (CA14161Y2006.SG) insider ownership and holdings - Yahoo Finance UK
Cardiol surpasses 50% enrollment in phase III pericarditis trial By Investing.com - Investing.com South Africa
Merger Talk: Will Cardiol Therapeutics Inc outperform the market in YEAR2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Cardiol Therapeutics Details 2025 Progress and Funding for Late-Stage Cardiac Drug Programs - TipRanks
Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis - marketscreener.com
Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis - TradingView
Cardiol surpasses 50% enrollment in phase III pericarditis trial - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) advances 2025 cardiac trials and funding - Stock Titan
Heart drug trial passes halfway mark as Cardiol funds work into 2027 - Stock Titan
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiol Therapeutics Achieves MAVERIC Enrollment Milestone Amidst Approaching Cash Runway Deadline - Bitget
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results - Stock Titan
Cardiol Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView — Track All Markets
Fed Meeting: Can Cardiol Therapeutics Inc maintain its current growth rateWeekly Profit Recap & Technical Buy Zone Confirmation - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Trading Up 10.5%Time to Buy? - MarketBeat
Earnings Recap: Can Cardiol Therapeutics Inc maintain its current growth rate2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Total debt of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Free cash flow of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Operating income of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Taxes of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Cardiol Therapeutics (TSX:CRDL) Expands Research Scope In Tsx Small Cap Index - Kalkine Media
If You Invested $1,000 in Cardiol Therapeu (CRDL) - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Shares Down 1.5%Time to Sell? - MarketBeat
Cizzle Brands Corporation Releases Fiscal Q2 2026 Results - Investing News Network
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - MSN
(CRDL) Trading Advice (CRDL:CA) - Stock Traders Daily
(CRDL) Optimized Trading Opportunities (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference - MarketBeat
1.06%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):